PDF(Pubmed)
Abstract：
Ameloblastoma, a benign yet aggressive odontogenic tumor known for its recurrence and the severe morbidity from radical surgeries, may benefit from advancements in targeted therapy. We present a case of a 15-year-old girl with ameloblastoma successfully treated with targeted therapy and review the literature with this question: Is anti-MAPK targeted therapy safe and effective for treating ameloblastoma? This systematic review was registered in PROSPERO, adhered to PRISMA guidelines, and searched multiple databases up to December 2023, identifying 13 relevant studies out of 647 records, covering 23 patients treated with MAPK inhibitor therapies. The results were promising as nearly all patients showed a positive treatment response, with four achieving complete radiological remission and others showing substantial reductions in primary, recurrent, and metastatic ameloblastoma sizes. Side effects were mostly mild to moderate. This study presents anti-MAPK therapy as a significant shift from invasive surgical treatments, potentially enhancing life quality and clinical outcomes by offering a less invasive yet effective treatment alternative. This approach could signify a breakthrough in managing this challenging tumor, emphasizing the need for further research into molecular-targeted therapies.
摘要：
成釉细胞瘤,一种良性但侵袭性的牙源性肿瘤，以其复发和根治性手术的严重发病率而闻名，可能受益于靶向治疗的进步。我们介绍了一例15岁女孩成釉细胞瘤的靶向治疗成功，并回顾了这个问题的文献：抗MAPK靶向治疗成釉细胞瘤安全有效吗？遵守PRISMA准则，并搜索了截至2023年12月的多个数据库，从647条记录中确定了13项相关研究，涵盖23例接受MAPK抑制剂治疗的患者。结果很有希望，因为几乎所有患者都表现出积极的治疗反应，其中4人实现了完全的放射学缓解，其他人则显示出原发性疾病的大幅减少，经常性,和转移性成釉细胞瘤的大小。副作用大多为轻度至中度。这项研究表明，抗MAPK疗法是侵入性手术治疗的重要转变，通过提供一种侵入性较小但有效的治疗替代方案，有可能提高生活质量和临床结局。这种方法可能意味着在治疗这种具有挑战性的肿瘤方面取得了突破，强调需要进一步研究分子靶向治疗。
